Background: Extended-spectrum beta-lactamases (ESBLs) may not always be detected in
routine susceptibility tests. This study reports the performance of the cefepime-clavulanate …

The worldwide dissemination of Enterobacteriaceae producing AmpC β-lactamases and
carbapenemases makes difficult the phenotypic detection of extended-spectrum β …

The purpose of this study was to simultaneously screen for Extended-spectrum β-
lactamases (ESBL) and AmpC β-lactamases in gram negative clinical isolates from four …

The acquisition of β-lactamases in members of the Enterobacteriaceae family poses a
challenge to antimicrobial susceptibility testing in the clinical laboratory. We correlated the …

Introduction: Few reports about the prevalence and genetic basis of extended spectrum beta-
lactamases (ESBLs) are available from Saudi Arabia. We sought to determine the …

Extended-spectrum β-lactamases (ESBLs) are plasmid-mediated bacterial enzymes that
confer resistance to a broad range of β-lactams. They are descended by genetic mutation …

Escherichia coli and Klebsiella pneumoniae isolates with extended-spectrum β-lactamases
(ESBLs) or AmpC cephalosporinases generally respond as predicted to NCCLS tests for …

Objectives: In this study, we evaluated the performance of a new ESBL Etest configuration
based on clavulanate synergy with cefepime compared with cefotaxime–clavulanate and …

Methods: One hundred consecutive, non-duplicate clinical isolates of K. pneumoniae
collected over a period of one year (June 2008-June 2009) were included in the study. An …

AmpC β-lactamases can interfere with extended-spectrum-β-lactamase (ESBL) confirmatory
tests. Resulting failures to detect ESBLs can endanger patients because false susceptibility …